Keratinocyte proliferation pathways

Keratinocyte proliferation pathways encompass multiple interconnected molecular mechanisms that regulate the growth and renewal of keratinocytes—the predominant cells forming the epidermis. Key structural proteins such as Keratins K5 and K14 maintain proliferative potential via modulation of intracellular signals including the PI3K/Akt pathway. The cytokine IL‑17 activates a novel cascade involving its receptor complex with Act1 adaptor protein leading through TRAF4–MEKK3–ERK5 kinase activation which sustains basal layer expansion via transcription factor p63. These processes are tightly balanced with differentiation programs controlled by Notch1 signaling.\n\nDysregulation contributes to pathological conditions including squamous cell carcinoma where aberrant activation promotes tumor formation. Therapeutic interventions aim at inhibiting critical kinases or receptors within these cascades to control hyperproliferation while preserving normal skin function. Additionally, Wnt-related non-canonical calcium-dependent routes influence cytoskeletal remodeling impacting migration alongside proliferation.\n\nOverall, understanding the molecular details underlying keratinocyte proliferation provides avenues for targeted therapies against cancers, inflammatory diseases, and impaired wound repair involving this essential epithelial cell type[1][2][3][4][6].

Other names

IL-17 signaling pathway in keratinocytesPI3K/Akt pathway in keratinocytesWnt signaling in keratinocytesKeratins 5Keratins 14

Drugs targeting these pathways act by:\n- Inhibiting kinase activity within proliferative signaling cascades such as PI3K/Akt or MEKK3–ERK5.\n- Blocking receptor-mediated activation signals like IL-17R engagement.\nThis results in reduced cell cycle progression and decreased tumorigenic potential[1][2][4].